- Home
- FAX vs CRMD Comparison
FAX vs CRMD Comparison
Compare FAX & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FAX | CRMD |
|---|---|---|
| Founded | 1986 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.9M | 876.7M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | FAX | CRMD |
|---|---|---|
| Price | $15.25 | $11.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.43 |
| AVG Volume (30 Days) | 833.6K | ★ 3.0M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 12.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.25 |
| Revenue | N/A | ★ $214,303,672.00 |
| Revenue This Year | N/A | $627.89 |
| Revenue Next Year | N/A | $40.95 |
| P/E Ratio | ★ N/A | $5.21 |
| Revenue Growth | N/A | ★ 1647.67 |
| 52 Week Low | $2.33 | $5.60 |
| 52 Week High | $2.84 | $17.43 |
Technical Indicators
Market Signals| Indicator | FAX | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 45.71 | 62.41 |
| Support Level | $15.13 | $10.90 |
| Resistance Level | $15.38 | $12.10 |
| Average True Range (ATR) | 0.17 | 0.49 |
| MACD | 0.02 | 0.24 |
| Stochastic Oscillator | 62.69 | 84.63 |
Price Performance
Historical ComparisonAbout FAX abrdn Asia-Pacific Income Fund Inc.
Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.